Previous experimentation with OSI-906, an (IGF1R)/insulin receptor (IR) tyrosine kinase inhibitor (TKI), revealed resistance to OSI-906 that was coupled with simultaneous activation of the MAPK pathway in CRC cell lines [50]. The gene discussed is INSR; the disease is colorectal carcinoma.